Establishment and Application of the Quality Control Technology System for Recombinant Drugs in China: A Review
RAO Chun-ming
National Institute for Food and Drug Control, Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, Beijing 100050, China
Abstract��In order to ensure the safety and effectiveness of biotech drugs, the CFDA has released a series of regulations and guidelines, and the NIFDC established an effective quality control technology system for recombinant drugs. This paper briefly reviews the important development stage of pharmaceutical biotechnology and the research and development situation of recombinant drugs in China, introduces in detail the establishment and application situation of the quality control technology system for recombinant drugs in the last 30 years in China, including the research basis and regulatory requirements for the quality standard, the quality standards of recombinant drugs in Chinese Pharmacopoeia Part �� and the quality control requirements for recombinant drugs in the current Pharmacopoeia, the support of national science and technology projects for establishing quality control system of biotechnology drugs by NIFDC and the establishment and application of the recombinant drug quality standards and all kinds of test methods such as the determination of biological activity and protein content, physical and chemical analysis and protein structural identification, determination of purity and impurity since 1986; development of national standards for biological activity and content determination, establishment and validation of the quality standards of the physical and chemical reference substances used for peptide mapping analysis and isoelectric point determination of recombinant drugs; analysis of inspection reports of a total of 5 920 batches of biotech drugs for all kinds of tests including registration inspection, import inspection, sample inspection, commission, and contracts tests completed by Division of Recombinant Biological Products, IBPC, and NIFDC since 2001.
�Ĵ���. �ҹ�����ҩ���������Ƽ�����ϵ�Ľ�����Ӧ���о�[J]. �й�ҩѧ��־, 2016, 51(13): 1057-1066.
RAO Chun-ming. Establishment and Application of the Quality Control Technology System for Recombinant Drugs in China: A Review. Chinese Pharmaceutical Journal, 2016, 51(13): 1057-1066.
RAO C M,DING L X. The study of quality standard of gene engineering drugs in China (��)[J]. China Pharm(�й�ҩʦ),2005,8(6):456-458.
[2]
RAO C M,DING L X. The study of quality standard of gene engineering drugs in China (��) [J]. China Pharm(�й�ҩʦ),2005,8(6):459-461.
[3]
TAO L,PEI D N,HAN C M,et al, Characterization and comparison of interferon reference standards using UPLC-MS[J]. Acta Pharm Sin(ҩѧѧ��),2015,50(1): 75-80.
[4]
FAN W H,TAO L,LI X,et al. Development of standardized methods for quality control of humanized monoclonal antibody HcHAb18 and structure confirmation of its reference substance for physicochemical analysis[J]. Chin New Drugs J (�й���ҩ��־),2014,23(20): 2360-2365.
[5]
TAO L, DING Y X,LIU L,et al. Identification of several kinds of post-translational modifications in recombinant protein pharmaceuticals using MS/MS[J]. Chin Pharm J(�й�ҩѧ��־),2015,50(19):1726-1730.
[6]
LEI YU, RAO C M, SHI X C, et al. A novel bioassay for the activity determination of therapeutic human brain natriuretic peptide (BNP) [J]. PLoS One,2012,7(11):1-8.
[7]
RAO C M,WANG J Z. Introduction of the related content of biotech drugs quality control in the Chinese Pharmacopoeia 2015[J]. Chin Pharm J(�й�ҩѧ��־),2015,50(20):1776-1781.
[8]
RAO C M,ZHANG X M, DING X S,et al. Improvement of trace peptide mapping by silver stain SDS-PAGE[J]. Prog Biochem Biophy(���ﻯѧ�����������չ),1989,16(3):241.
[9]
RAO C M,LI Z G,DING X S, et al. Assay of exogenous DNA in rhIFN-��1b with biotin labelled DNA probe[J]. Chin J Biol(�й�������Ʒѧ��־),1990,3(2):70-72.
[10]
WNAG J Z, RAO C M, ZHANG Y,et al. The quality control standard of biotech drugs in China, the standard of research and develop [Z]. Database of CHKD national scientific and technological achievements (CHKD���ҿƼ��ɹ����ݿ�), 2004.
[11]
RAO C M, LIU L, WANG J Z. Assay for bioactivity determination of recombinant basic fibroblast growth factor[J]. J Microbiol(����ѧ��־),1999,19(3):41-42.
[12]
FANW H, BI H, RAO C M, et al. Development of a method for determination of biological activity of humanized rabbit anti-vascular endothelial growth factor monoclonal antibody[J]. Chin J Biol(�й�������Ʒѧ��־), 2012,12(3):367-369,374.
[13]
YANG Y S,ZHOU Y,YU L,et al. A novel reporter gene assay for recombinant human erythropoietin (rhEPO) pharmaceutical products[J]. J Pharm Biomed Anal,2014,100 (8): 316-321.
[14]
RAO C M, PEI D N, YU L, et al. Evaluation of a reporter gene assay for bioactivity determination of therapeutic interferons through a collaborative study[J]. Curr Pharm Anal, 2016, 12(2): 129-136.
[15]
YU L, FAN W H, WANG L, et al. Reporter gene assay for bioactivity determination of exendin-4-HAS[J]. Chin J Pharm Anal(ҩ�������־),2016,36(3):426-431.
[16]
GAO K, RAO C M, TAO L, et al. Development and calibration of a standard for the protein content of granulocyte colonystimulating factor products[J]. Biologics, 2012,40(2):151-157.
[17]
LIU L, SHI X C, HAN C M, et al. Protein content determination and specific activity analysis of recombinant human G-CSF final products[J]. Chin J Pharm Anal(ҩ�������־),2013,33(5): 785-787.
[18]
LI Y H, PEI D N, TAO L, et al. Development of size exclusion-high performance liquid chromatography method for determination of protein content in final product of recombinant human interferon ��2a[J]. Chin J Biol(�й�������Ʒѧ��־),2013, 26(8):1175-1178.
[19]
DING Y X,HAN C M,BI H, et al. SEC-HPLC chromatography method for determination of rhTNK-tPA��s single-chain content[J]. Chin J Pharm Anal(ҩ�������־), 2014, 34(7):1208-1211.
[20]
BI H, SHI X C,RAO C M, et al. Application of amino acid analysis in quality control of recombinant protein biologics[J]. Chin J Biol(�й�������Ʒѧ��־),2016,29 (2):188-191.
[21]
RAO C M,ZHANG Y,HAN C M,et al. Peptide mapping analysis of recombinant human Interleukin-11 by tryptic digestion[J]. Acta Pharm Sin(ҩѧѧ��),2000,35(5): 378-380.
[22]
YANG Y, RAO C M, WANG W. Identification of rhIL-11 by HPLC-ESI-Q-TOF-MS spectrometry[J]. J Chin Mass Spectrometry Soc(����ѧ��), 2006,27 (2):117-121.
[23]
TAO L, RAO C M, GAO K. Structure verification of a recombinant chimeric anti-CD20 IgG1 monoclonal antibody[J]. Acta Pharm Sin(ҩѧѧ��),2010, 45 (6): 752-755.
[24]
TAO L, RAO C M, GAO K. Effect of theoligosaccharides IgG1 on its structure and function[J]. Chin J Pharm Anal(ҩ�������־),2011, 31 (11):2095-2098.
[25]
LI M, PEI D N, TAO L. Analysis of primary structure of recombinant antitumor-antivirus protein by liquid chromatography-mass spectrometry[J]. Chin J Biol(�й�������Ʒѧ��־),2011, 24 (12):1473-1476.
[26]
LI X, GAO X D, TIAN H. Development of capillary isoelectric focusing electrophoresis method for analysis of isoelectric point of fusion protein FP3[J]. Chin J Biol(�й�������Ʒѧ��־),2012,25(4):483-486.
[27]
TAO L, DING Y X, GUO Y. Characterization of the primary structure of TNK-tissue plasminogen activator using LC-MS[J]. Acta Pharm Sin(ҩѧѧ��), 2013,48(6):896-900.
[28]
RAO C M,WANG J Z,GAO K,et al. Determination of residual E. coli bacteria proteins in recombinant cytokines by ELISA[J]. Chin J Biol(�й�������Ʒѧ��־),2000,13(1):43-46.
[29]
LI Y, RAO C, TAO L. Improved detection of variants in recombinant human interferon alpha-2a products by reverse-phase high-performance liquid chromatography on a core-shell stationary phase[J]. J Pharm Biomed Anal,2013,28(88C):123-129.
[30]
LI Y H, LI X, HAN C M. Quantitation of free polyethylene glycol in PEGylated interferon alpha-2a injection by HPLC-ELSD[J]. Pharm Biotechnol(ҩ�����＼��), 2014,21(4):353-354.
[31]
BI H, FAN W H, SHI X C. Development of a method for determination of residual protein A of a kind of Fc fusion protein[J]. Chin J Pharm Anal(ҩ�������־),2014,34(2):297-300.
[32]
LI Y H, HAN C M, PEI D N. Comparison of two methods in analyzing recombinant human interferon ��-2b related proteins[J]. Chin J Pharm Anal(ҩ�������־),2014,34(7): 1204-1207.
[33]
WANG C, LI Y H, FU Z H. Development and verification of SYBR green �� real-time PCR method for quantitative detection of reverse transcriptase activity in cell lines[J]. Chin J Biol(�й�������Ʒѧ��־),2014,27(8):1061-1065.
[34]
LI Y H, WANG J Z, HAN C M,et al. Methods for recombinant human endostatin[J]. Acta Pharm Sin(ҩѧѧ��),2002,37(10):807-811.
[35]
RAO C M, WANG J Z, ZHAO Y. Study of the requirements and methods for quality control of recombinant human brain natriuretic peptide[J]. Chin J Pharm Anal(ҩ�������־), 2002,22(5):346-349.
[36]
YUAN L Y, RAO C M, GUO Y, et al. Method for determination of biological activity and standard for quality control of recombinant human neuregulin[J]. Chin J Biol(�й�������Ʒѧ��־),2004,17(6):374-376.
[37]
ZHANG Y, HAN C M, GAO K, et al. Study on methods and requirements for quality control of pegylated recombinant human G-CSF[J]. Drug Stand China(�й�ҩƷ��), 2004,5(2):10-12.
[38]
DING Y X,HAN C M, LI X. Study on the specification for quality control of human tissue urokinase plasminogen(HTUPA) [J]. Chin J Pharm Anal(ҩ�������־), 2007,27(6):787-790.
[39]
DING Y X, LI X, HAN C M, et al. Development of methods and standard for quality control of recombinant human pro-urokinase[J]. Chin J Biol(�й�������Ʒѧ��־),2007,20(7):515-518.
[40]
PEI D N, RAO C M, LI Y H. Establishment of quality control methods and standards for recombinant antitumor-antivirus-protein novaferon[J]. Chin J Cancer Biother(�й���������������־),2009,16(3):364-368.
[41]
WANG L, RAO C M, TAO L. Study on methods and requirements for quality control of vascular endothelial growth factor inhibitor[J]. Chin J Pharm Anal(ҩ�������־), 2010,30(6):977-982.
[42]
BI H, FAN W H, HAN C M. Study on quality control methods and standards of recombinant humanized rabbit anti-VEGF mAb[J]. Chin J Pharm Anal(ҩ�������־),2012,32(6):1054-1058.
[43]
DING Y X, HAN C M, LIU L. Development of methods for quality control of recombinant human tenecteplase[J]. Chin J Biol(�й�������Ʒѧ��־),2013, 26(7): 1015-1017.
[44]
DING Y X, HAN C M. Development of methods and standards for quality control of recombinant staphylokinase-hirudin fusion protein[J]. Chin J Biol(�й�������Ʒѧ��־), 2014, 27(8):1024-1028.
[45]
TAO L, HAN C M, CHEN W. Study of methods and standards for quality control of recombinant interleukin-22-Fc fusion protein[J]. Chin J Pharm Anal(ҩ�������־),2015,35(4):591-594.
[46]
BI H, LI Y H, YANG J Q. Establishment of method and requirement for quality control of recombinant human tumor necrosis factor-related apoptosis-inducing ligand mutant[J]. Chin J Biol(�й�������Ʒѧ��־),2016,29 (3):270-274.
ZHANG Z Q, GUO Y, ZHANG Y J. Preparation of the human interleukin-2 for national standard and its characteristics[J]. Chin J Cancer Biother(�й���������������־),1998,5(4):269-273.
[49]
ZHANG Y,RAO C M,WANG J Z, et al. Preparation of reference for determining the activity of recombinant staphylokinase[J]. Chin J Biol(�й�������Ʒѧ��־),1999,12(1):52-54.
[50]
WANG J Z, GAO K, RAO C M. Collaborative study of the national standard for recombinant human tumor necrosis factor ��(rhTNF-��) [J]. Chin J Cancer Biother(�й���������������־), 1999, 6(4):295-298.
[51]
ZHANG Y, DING Y X,RAO C M, et al. Preparation of national standards of recombinant streptokinase[J]. Chin J Biol(�й�������Ʒѧ��־),2000,13(4):237-238.
[52]
RAO C M, LIU L,DING Y X,et al. Preparation of the national standard of recombinant bovine basic fibroblast growth factor[J]. Chin J Biol(�й�������Ʒѧ��־),2001,14(2):94-96.
[53]
RAO C M, ZHAO Y,DING Y X,et al. Preparation of the national standard of recombinant human granulocyte colony-stimulating factor for bioassay[J]. Chin J Biol(�й�������Ʒѧ��־), 2001,14(2):231.
[54]
ZHAO Y, RAO C M, ZHANG Y,et al. Preparation of the national active assay standard for recombinant human granulocyte-macrophage colony stimulating factor[J]. Chin J Cancer Biother(�й���������������־), 2001,8(3): 205-207.
[55]
LIU L, RAO C M, DING Y X. Preparation of the national standard of recombinant human epidermal growth factor for bioassay[J]. Chin J Biol(�й�������Ʒѧ��־), 2002,15(3):175-176.
[56]
PEI D N, RAO C M, GUO Y, et al. Preparation of national standard for determination of activity of recombinant human interferon ��1b[J]. Chin J Biol(�й�������Ʒѧ��־),2009,22(12):1206-1209.
[57]
PEI D N, GUO Y, DING Y X. Preparation of the first national bioactivity standard for recombinant human interferon ��2b[J]. Chin J Biol(�й�������Ʒѧ��־),2014,27 (9):1173-1180.
[58]
GAO K, DING Y X, ZHANG Y. Establishment and calibration of the fourth batch national standard substance for protein content determination[J]. Chin J Pharm Anal(ҩ�������־), 2007,27(8):1215-1217.
[59]
WANG L, RAO C M, GAO K. Development of a reference standard of escherichia coli DNA for residual DNA determination in China[J]. PLOS One,2013,8(9):1-6.
[60]
WANG L, GAO K, FAN W H. Preparation of national standard substance of CHO cell DNA[J]. Chin Pharm J(�й�ҩѧ��־),2013,48(1):68-72.
[61]
LIU L, SHI X C, RAO C M. Bioactivity of recombinant human granulocyte colony-stimulating factor[J]. Chin J Biol(�й�������Ʒѧ��־),2013,26(4):521-527.
[62]
PEI D N,GUO Y,LI Y H,et al. Sampling results and quality assessment of recombinant human interferon��2a injections[J]. China Pharm (�й�ҩʦ), 2015,18(1): 52-55.
[63]
DING Y X, PEI D M, LI Y H. Sampling results and quality assessment of recombinant human interferon ��2b injection in 2013[J]. Prog Mod Biomed(�ִ�����ҽѧ��չ),2014, 14(36): 7160-7164.
[64]
SFDA. Guidelines for Study of Human Recombinant DNA Product Quality Control(��������DNA ��Ʒ�������Ƽ���ָ��ԭ��) [S]. 2003.
[65]
SFDA. Guidelines for Study of Human Monoclonal Antibody Quality Control(���õ���¡�����������Ƽ���ָ��ԭ��)[S]. 2003.
2016, Vol. 51 
